Short answer
RxSight, Inc. (RXST) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $27M (down 19.0% year over year) with net income of −$12M.
Q2 2026 key financials · XBRL
- Revenue
- $27M
- −19.0% YoY · −11.8% QoQ
- Net income
- −$12M
- −2.6% YoY · +23.8% QoQ
- Operating margin
- -50.5%
- EPS (diluted)
- −$0.30
- −3.4% YoY · +21.1% QoQ
Source: XBRL data from the RxSight, Inc. (RXST) Q2 2026 10-Q on SEC EDGAR. USD.
RxSight, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin percentages provided in excerpt
- Installed base 1,166 LDDs; approximately 357,000 LALs implanted through June 30, 2026
- Expected continued net losses and negative operating cash flows in near term
- July leadership transition, pipeline updates, and Alcon collaboration agreement; 3,500,000 shares reserved under inducement plan
Risk Factors
- New Alcon collaboration risk triggered by June 2026 agreement, with $70 million feasibility and $40 million approval payments contingent on Alcon election
- Most material commercial update: sales declined in 2025 and first-half 2026, prompting Customer Success Organization realignment
- Legal risk: putative securities class action complaint filed July 2025 remains pending in the Central District of California
- Competitive and operational risk: single-source suppliers expose RxSight system components to supply disruptions and price fluctuations
- Liquidity risk: cash, cash equivalents and short-term investments declined to $208.8 million at June 30, 2026 from $228.1 million at December 31, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RxSight, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.